SEC Contract Filing

Filing Date: 2021-06-14

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ea142642ex10-1_avalonglobo.htm
<DESCRIPTION>SECURITIES EXCHANGE AGREEMENT, DATED JUNE 13, 2021, AMONG AVALON GLOBOCARE CORP, LONLON BIOTECH LTD., SENLANG BIOTECHNOLOGY CO. LTD. AND YUEYIN DATONG (TIANJIN) ASSET MANAGEMENT CO. LTD.
<TEXT>
<HTML>
<HEAD>
 <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SECURITIES
exchange AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Exchange Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is dated as of June 13, 2021, among Avalon GloboCare Corp., a Delaware corporation (the &ldquo;Company&rdquo;),
Lonlon Biotech Ltd., a company incorporated in the British Virgin Islands (&ldquo;Sen Lang&rdquo;), Senlang Biotechnology Co. Ltd. (<FONT STYLE="font-family: Times New Roman, Times, Serif">&#27827;&#21271;&#26862;&#26391;&#29983;&#29289;&#31185;&#25216;&#26377;&#38480;&#20844;&#21496;</FONT>
in Chinese), a company with limited liability organized and existing under the laws of the PRC (the &ldquo;<U>OpCo</U>&rdquo;), and Yueyin
Datong (Tianjin) Asset Management Co. Ltd. (in Chinese, <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&#32422;&#21360;&#22823;&#36890;&#65288;&#22825;&#27941;&#65289;&#36164;&#20135;&#31649;&#29702;&#26377;&#38480;&#20844;&#21496;),
a limited liability company</B></FONT> organized and existing under the laws of the People&rsquo;s Republic of China (including its successors
and assigns, &ldquo;<U>Purchaser</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company has entered
into certain Share Purchase Agreement (the &ldquo;Acquisition Agreement&rdquo;) dated as of June 13, 2021, with <U>Sen Lang</U>), the
holders of shares of Sen Lang capital stock and the other parties named therein, and upon the closing of the Acquisition Agreement, the
Company will become 100% parent-owner of Sen Lang;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Lonlon Biotech Investment
Limited (the &ldquo;HK Subsidiary&rdquo;) is a wholly owned subsidiary of Sen Lang that is organized and existing under the laws of Hong
Kong Special Administrative Region (&ldquo;<U>Hong Kong</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Beijing Langlang
Runfeng Biotechnology Co., Ltd. (<FONT STYLE="font-family: Times New Roman, Times, Serif">&#21271;&#20140;&#26391;&#26391;&#28070;&#20016;&#29983;&#29289;&#31185;&#25216;&#26377;&#38480;&#20844;&#21496;</FONT>
in Chinese) is a wholly foreign owned enterprise with limited liability organized and existing under the laws of the People&rsquo;s Republic
of China (the &ldquo;<U>PRC</U>&rdquo;, for the purpose of this Agreement, excluding Hong Kong, the Macau Special Administrative Region
and Taiwan) (the &ldquo;<U>PRC Subsidiary</U>&rdquo;). The PRC Subsidiary is a wholly-owned company of the HK Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the OpCo is mainly
engaged in the business of the research and development in relation to CAR-T cell therapy, immune cell therapy and related drug (the &ldquo;<U>Principal
Business</U>&rdquo;). Thirteen (13) out of the total fifteen (15) Sen Lang Beneficial Shareholders own the aggregate 100% equity interests
in the OpCo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the PRC Subsidiary
has entered into a set of variable interest entities agreements (such agreements are collectively referred to as the &ldquo;<B>VIE Agreements</B>&rdquo;,
and such contractual control arrangement is referred to as the &ldquo;<B>VIE Structure</B>&rdquo;) with the OpCo and each of its equity
holder, to establish and maintain the OpCo&rsquo;s intended captive structure, under which the financial statements of the OpCo can be
consolidated with those of the other subsidiaries of Sen Lang in accordance with its then duly adopted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;<U>Securities
Act</U>&rdquo;), and Rule 506 promulgated thereunder, the Company desires to provide each Purchaser with the right to exchange the Registered
Capital of the Op